The invention relates to a pharmaceutical liposomal composition comprising 2-{[5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy}-3-(2-{[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy}phenyl)propanoic acid, referred to herein as 'Compound A', or a pharmaceutically acceptable salt thereof. More specifically the invention relates to a liposomal vehicle, an organic concentrate composition comprising Compound A, and a pharmaceutical composition for parenteral administration comprising liposomes and Compound A. Furthermore, the invention relates to the use of such compositions for the treatment of cancer. 'Compound A' as used herein includes all enantiomers, diastereoisomers, and atropisomers thereof, or mixtures thereof, and also optionally includes the pharmaceutically acceptable salts thereof.本發明係關於一種醫藥脂質體組合物，其包含在本文中稱作『化合物A』之2-{[5-{3-氯-2-甲基-4-[2-(4-甲基哌嗪-1-基)乙氧基]苯基}-6-(4-氟苯基)噻吩并[2,3-d]嘧啶-4-基]氧基}-3-(2-{[2-(2-甲氧基苯基)嘧啶-4-基]甲氧基}苯基)丙酸或其醫藥學上可接受之鹽。更特定言之，本發明係關於脂質體媒劑、包含化合物A之有機濃縮物組合物及用於非經腸投與之包含脂質體及化合物A的醫藥組合物。此外，本發明係關於此類組合物用於治療癌症之用途。如本文中所使用之『化合物A』包括所有對映異構體、非對映異構體及其滯轉異構體或其混合物，且亦視情況包括其醫藥學上可接受之鹽。
